{"id":"W4406124968","doi":"10.1177/17588359241308784","title":"The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; William Osler Health System; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Dalhousie University; University of Toronto; University of Manitoba; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital; CancerCare Manitoba; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Eli Lilly Canada; Bayer Canada; Pfizer Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; EMD Serono; Astellas Pharma; Genentech; AstraZeneca Canada; Amgen Canada; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Epidermal growth factor receptor; KRAS; Anaplastic lymphoma kinase; Medicine; Crizotinib; Cancer research; Lung cancer; ROS1; Erlotinib; Clinical trial; Biomarker; EGFR inhibitors; Cancer; Targeted therapy; Oncology; Internal medicine; Biology; Adenocarcinoma; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006466199,0.00047968,0.002591272,0.0003221767,0.0000885172,0.000009965563,0.0005557513,0.0005876872,0.000191165],"category_scores_gemma":[0.0002029286,0.0002879844,0.0003241628,0.0007531578,0.0003566853,0.00008059439,0.0001212042,0.0009448369,0.000002231163],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008304418,"about_ca_system_score_gemma":0.006057138,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006495784,"about_ca_topic_score_gemma":0.001727283,"domain_scores_codex":[0.9967597,0.000284564,0.001369533,0.0005435854,0.0004683063,0.0005743804],"domain_scores_gemma":[0.995671,0.002918816,0.0006614895,0.0004582375,0.0001486513,0.0001418419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001240817,0.0006455212,0.001008226,0.006917362,0.0004604179,0.00007067544,0.0007249557,0.00003915323,0.000004556072,0.0001607779,0.00004123592,0.989803],"study_design_scores_gemma":[0.006372998,0.0004346048,0.0001352441,0.02529933,0.001589745,0.00002679136,0.0005926,0.0004787159,0.00000315291,0.00006103394,0.9647338,0.0002720091],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001276041,0.9870696,0.000641808,0.0007419565,0.0009057218,0.002247158,0.00003695147,0.00002529083,0.008203927],"genre_scores_gemma":[0.000706977,0.9948339,0.001192362,0.0005596105,0.0001705162,0.001477379,0.00004751376,0.00005115859,0.0009605878],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.989531,"threshold_uncertainty_score":0.9999572,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02203002502274497,"score_gpt":0.4331020654722201,"score_spread":0.4110720404494751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}